Heat Biologics, Inc. HTBX
At closeMay 3, 2022, 12:00 AM EDT
52-week range unavailable
- Market cap
- 61.05M
- Revenue (ttm)
- 2.11M
- Shares out
- 25.65M
- Forward P/E
- -1.62
- Volume
- 43.61K
- Open
- 2.41
- Previous close
- 2.38
- Day's range
- 2.33 – 2.48
- Beta
- 0.30
- Analysts
- Buy
- Price target
- 11.38 (+378.2%)
- Earnings date
- May 4, 2022
2Y -2.95 (-55.35%)
Key statistics
- Enterprise value
- -34.74M
- PEG ratio
- 0.00
- Price / sales
- 28.89
- Price / book
- 0.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1.60%
- Free cash flow
- -16.18M
- Total cash
- 96.38M
- Total debt
- 1.93M
- Return on equity
- -31.12%
- Short % of float
- 0.00%
- 50-day average
- 2.57
- 200-day average
- 4.11
Analyst view
Consensus: buy
- Target (low)
- 8.00
- Target (mean)
- 11.38
- Target (high)
- 15.50
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
May 4, 2022
Expected May 4, 2022. Consensus EPS estimate -0.49.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 4, 2022 | Mar 1, 2022 | -0.46 | — | — | — |
| Mar 14, 2022 | Dec 1, 2021 | -0.31 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -0.29 | — | — | — |
| Aug 11, 2021 | Jun 1, 2021 | -0.28 | — | — | — |
| May 5, 2021 | Mar 1, 2021 | -0.29 | — | — | — |
| Apr 5, 2021 | Dec 1, 2020 | -0.37 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 3, 2021 | Cantor Fitzgerald | init | — | Overweight |
| Oct 14, 2020 | B. Riley FBR | init | — | Buy |
| Feb 6, 2020 | Maxim Group | init | — | Buy |
| Jul 30, 2019 | Brookline Capital | init | — | Buy |
| Jun 26, 2018 | H.C. Wainwright | init | — | Buy |
| Jun 20, 2016 | Roth Capital | init | — | Buy |
About Heat Biologics, Inc.
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- heatbio.com
News
Stocks That Hit 52-Week Lows On Tuesday 
Stocks That Hit 52-Week Lows On Thursday 
Stocks That Hit 52-Week Highs On Wednesday - Stocks That Hit 52-Week Highs On Friday
- 50 Stocks Moving in Thursday's Pre-Market Session
31 Stocks Moving in Monday's Pre-Market Session 
Stocks That Hit 52-Week Highs On Tuesday 
Stocks That Hit 52-Week Highs On Monday - 85 Biggest Movers From Yesterday
50 Stocks Moving In Tuesday's Mid-Day Session
Your note
Sign in to keep a note on HTBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUTCHINS JEFF TOBIN PH.D. | Officer | Stock Award(Grant) | Dec 31, 2018 | 143,140 |
| OSTRANDER WILLIAM L. | Officer | Conversion of Exercise of derivative security | Aug 12, 2020 | 11,185 |
| PRENDERGAST JOHN K. A. PH.D. | Director | Stock Award(Grant) | Jan 1, 2020 | 700,000 |
| ROSAR ANN A | Officer | Stock Award(Grant) | Dec 31, 2018 | 93,379 |
| SMITH EDWARD B III | Director | Sale | Nov 11, 2020 | 0 |
| WOLF JEFFREY ALAN J.D. | Chief Executive Officer | Stock Award(Grant) | Jan 1, 2020 | 3,943,950 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 4.32% | 1,097,329 | 3.36M | Mar 30, 2022 |
| Blackrock Inc. | 1.86% | 471,910 | 1.44M | Mar 30, 2022 |
| Geode Capital Management, LLC | 0.98% | 249,540 | 763.59K | Mar 30, 2022 |
| LPL Financial LLC | 0.52% | 133,054 | 407.14K | Mar 30, 2022 |
| State Street Corporation | 0.41% | 102,983 | 315.13K | Mar 30, 2022 |
| Morgan Stanley | 0.30% | 75,936 | 232.36K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.78% | 705,534 | 2.14M | Dec 30, 2021 |
| Vanguard Extended Market Index Fund | 1.39% | 353,502 | 1.07M | Dec 30, 2021 |
| Fidelity Extended Market Index Fund | 0.63% | 159,438 | 414.54K | Feb 27, 2022 |
| iShares Micro Cap ETF | 0.24% | 60,312 | 176.11K | Jan 30, 2022 |
| IndexIQ ETF Tr-IQ Chaikin U.S. Small Cap ETF | 0.23% | 57,966 | 150.71K | Feb 27, 2022 |
| DFA U.S. Small Cap Series | 0.16% | 41,165 | 120.20K | Jan 30, 2022 |